09:43 AM EST - Fennec Pharmaceuticals Inc. : Reported its financial results for the fiscal year ended December 31, 2023. Net losses for the fourth quarter and year ended December 31, 2023, of $2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively, compared to $6.9 million ($0.26 per share) and $23.7 million ($0.90 per share), respectively, for the same periods in 2022. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $13.18.
